---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-043431"
form_type: "8-K"
ticker: "WGS"
cik: "0001818331"
company_name: "GeneDx Holdings Corp."
filed_at: "2026-06-16T12:39:37+00:00"
generated_at: "2026-06-16T12:45:08.695208+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# GeneDx names Mark Gardner as President, effective June 15, 2026

## Summary
- Mr. Gardner, former Quest Diagnostics SVP, will oversee lab and commercial ops, reporting to CEO Katherine Stueland.
- Compensation includes $530K base salary, 65% target bonus, and $2M RSU grant vesting over four years.
- Bryan Dechairo transitions to lead product, technology and innovation initiatives.
- Gardner previously served as CEO of OmniSeq and held senior roles at Thermo Fisher Scientific and Life Technologies.

## SEC filing metadata
- accession: 0001628280-26-043431
- form_type: 8-K
- ticker: WGS
- cik: 0001818331
- company_name: GeneDx Holdings Corp.
- filed_at: 2026-06-16T12:39:37+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818331/000162828026043431/0001628280-26-043431-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818331/000162828026043431/wgs-20260615.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-043431
- JSON: https://secwatch.observer/filing/0001628280-26-043431.json
- Plain text: https://secwatch.observer/filing/0001628280-26-043431.txt

## Key facts
- Executive change
  Bryan Dechairo changed role as other at GeneDx Holdings Corp..
  - Action: transitioned
  source text: Following Mr. Gardner’s appointment, Bryan Dechairo will transition into a role focused on leading the Company’s product, technology and innovation initiatives.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818331/000162828026043431/0001628280-26-043431-index.htm
- Executive change
  Mark Gardner was appointed as President at GeneDx Holdings Corp..
  - Action: appointed
  - Role: President
  source text: On June 16, 2026, GeneDx Holdings Corp. (the “Company”) announced the appointment of Mark Gardner, age 60, in the role of President, which was effective on June 15, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818331/000162828026043431/0001628280-26-043431-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.